Represented by SHIVAJI SINGH SAMEER CHAVAN SOURIMA MUKHERJEE SONAL KULKARNI SUVARNA CHAVAN M.Sc (CLINICAL RESEARCH) (CRANFIELD)GROUP-9.

Slides:



Advertisements
Similar presentations
Parkinsons Disease Management in Primary Care. Introduction Progressive condition 1:500 whole population 1:50 of elderly 1:10 Nursing Home Residents.
Advertisements

Drugs That Act On The Central Nervous System SAMUEL AGUAZIM( MD)
Parkinson's Disease Animal Models and Possible Treatments.
ILOs At the end of this lecture you will be able to:- Recognize the symptoms and pathophysiology of parkinsonism. Understand the pharmacology of drugs.
ILOs At the end of this lecture you will be able to:- Revew the symptoms and pathophysiology of parkinsonism. Detail on the pharmacology of drugs used.
Parkinson’s Disease (PD)
The PARticulars of Parkinson’s Disease
Copyright © 2014 by Mosby, an imprint of Elsevier Inc.
Drugs Used to Treat Parkinson’s Disease By Jasmine and Morgan 11/13/03.
Initial Diagnosis and Management of Parkinson’s Disease
Parkinson’s Disease and Treatment Shalla Hanson Medicinal Chemistry April 2009.
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins Anticonvulsants and Antiparkinsonism Drugs Chapter 5.
Parkinson ’ s disease. Function Anatomy of Parkinson ’ s Disease.
Mosby items and derived items © 2011, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc. CHAPTER 16 Antiparkinsonian Drugs.
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. CHAPTER 14 Antiparkinsonian Drugs.
Chapter 30 Agents Used to Treat Parkinson’s Disease.
Objectives Description of Parkinson's disease
Anti Parkinson's Drugs Parkinsonism
Drugs for Parkinon’s disease Parkinson's disease –progressive tremor –Bradykinesia and rigidity –degeneration of the dopaminergic nigrostriatal pathway.
Drugs of Anti-Parkinson’s disease Department of Pharmacology Zhang Yan-mei.
Treatment of Parkinson’s Disease Thomas L. Davis, M.D. Associate Professor of Neurology Vanderbilt School of Medicine.
Chapter 31 Anti-Parkinson Agents. Copyright 2007 Thomson Delmar Learning, a division of Thomson Learning Inc. All rights reserved Parkinson’s.
By Prof. Hanan Hagar Pharmacology unit Medical College.
Drugs For Parkinson's Disease. History of Parkinson's Disease l First characterized in 1817 by James Parkinson : An Essay On The Shaking Palsy.
Adult Medical-Surgical Nursing Neurology Module: Parkinson’s Disease.
Salvador Dali (Painter) Mao Zedong (Chinese Politician) Michael J Fox (Actor) Pope John Paul II Muhammad Ali (Boxer) Janet Reno (Former AG)
Treatment of Parkinson’s Disease Christopher Buchanan CHEM 5398/Buynak April 3, 2007.
Slide 1 Copyright © 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc. Chapter 13 Drugs Affecting the Autonomic Nervous System.
 Parkinson Disease (PD) is a disorder of the brain that causes a variety of movement problems.
Slide 1 Mosby items and derived items © 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc. Chapter 15 Drugs Used for Parkinson’s Disease.
Drugs used in parkinsonism
By Prof. Hanan Hagar Pharmacology unit Medical College.
By Prof. Hanan Hagar Pharmacology unit Medical College.
1 Copyright © 2012, 2009, 2006, 2003 by Saunders, an imprint of Elsevier Inc. Chapter 23 DRUGS FOR NEUROLOGIC DISORDERS: PARKINSONISM AND ALZHEIMER’S DISEASE.
Parkinson's Disease ILOs
By Katelyn Chaimson and Sean Guyot
Drugs in parkinsonism ilos
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. CHAPTER 14 Antiparkinsonian Drugs.
Drugs Used for Parkinson’s Disease Chapter 15 Mosby items and derived items © 2010, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc.
CNS -Antiparkinsonian Drugs Discuss the signs and symptoms exhibited by a patient with Parkinson’s Disease Describe the actions and intended effects of.
ANTI- PARKINSONISM Dr: Samah Gaafar Al-shaygi.  Neurodegenerative diseases.  Dopamenergic neurones in substantia nigra.  Environmental* genetic factors.
 Parkinson’s disease is a neurodegenerative disorder first described by Dr James Parkinson, a London physician, in The underlying cause is loss.
Neurotransmitters in the brain By Joon Kim. Neurotransmitters  A neurotransmitter is a specialized messenger chemical that transfers or sends information.
ANTI-PARKINSONIAN DRUGS. Parkinsonism It is a common movement disorder that involves dysfunction in the basal ganglia and associated brain structures.
CHAPTER 28 Pharmacologic Management of Parkinsonism and Other Movement Disorders.
Drug Therapy for Parkinson’s Disease
Parkinson’s disease by Syed Baseeruddin Alvi (09).
Pharmacology Nursing C ONTINUE CNS D RUGS Lecture 7.
Parkinson's disease.
Drugs Used for Parkinson’s Disease
Parkinsonism.
DRUGS FOR PARKINSONISM
Pharmacologic Management of Parkinson disease (PD)
Drugs of Anti-Parkinson’s disease
Lecture 3 Dr.Narmin Hussen
Drugs for Parkinson’s Disease
Treatment of Parkinson’s disease
ANTIPARKINSONS Drugs By Dr. Mirza Shahed Baig.
Parkinsonism: MAO-i, COMT-i and other
Central Nervous System
Parkinsonism and Anesthesia
מחלת פרקינסון מחלת פרקינסון היא מחלה Progressive.
Anti-parkinsonism Drugs
Anti-parkinsonism Drugs
Introduction to Clinical Pharmacology Chapter 28 Antiparkinson Drugs
Antiparkinsonian drugs Presented by K.Lakshmi Department of pharmacology Assistant professor SSPC.
Drugs for Degenerative Diseases of the Nervous System
Classification of Epilepsy (p. 227)
Management in Primary Care
Introduction to Clinical Pharmacology Chapter 28 Antiparkinson Drugs
Presentation transcript:

Represented by SHIVAJI SINGH SAMEER CHAVAN SOURIMA MUKHERJEE SONAL KULKARNI SUVARNA CHAVAN M.Sc (CLINICAL RESEARCH) (CRANFIELD)GROUP-9

 Neuro-degenerative disorder.  caused by a deficiency of dopamine and an excess of acetylcholine within the CNS.  Affects the part of the brain that controls muscle movement, causing symptoms as trembling, rigidity.

 Multidisciplinary management is essential 1. Drug therapy 2. Physiotherapy 3. Occupational therapy 4. Speech and language therapy 5. Nursing 6.Surgical treatment 7.Gene therapy

 Divided into two broad classes: 1. Dopaminergic drugs 2. Anticholinergic drugs

 Divided into six sub classes 1. Dopaminergic precursor - levodopa 2. Peripheral decarboxylase inhibbtor - carbidopa -benserazide 3. MAO-B inhibitor -selegiline -rasagiline

4. Dopamine agonists 4.1. ERGOT DERIVATIVES 4.2. NON ERGOT DERIVATIVES -lusiride -piribedil -bromocriptine -rotigotin -pregolide -ropinirole 5. Dopamine facilitator -amantadine 6. COMT inhibitor (catechol-O-methyltransferase) -entacapone -tolcapone

 No change in muscle tone.  Reversal of tremor requires continued therapy.  Changes in mood associated with parkinsonism are reversed.

 95% of l-dopa is metabolized in the periphery to dopamine.  Only a small portion entering the brain.

 Choreiform or dystonic  movements, anorexia, abdominal pain,  dysphagia, dry mouth, mental  changes, headache, dizziness,  increased hand tremor, peripheral edema,  constipation  hallucinations, confusion,  depression, loss of balance

 Contraindicated in patients with narrow-angle glaucoma,those receiving a monoamine oxidase inhibitor.  Used with caution in patients with tachycardia, cardiac arrhythmias, hypertension, hypotension.  Cautious administration in patients with obstructive disease of the urinary system or gastrointestinal tract.

 Divided into two sub classes 1. Anticholinergic drugs -benztropine -procyclidine -biperiden 2. Antihistamines drugs -diphenhydramine -orphenadrine -promethzine

 Inhibit acetylcholine in the CNS.  Less effective than levodopa.

 Dry mouth, blurred vision, dizziness, mild nausea, and nervousness.  Skin rash, urinary retention, tachycardia, muscle weakness, disorientation, and confusion.

 Contraindicated in patients with a hypersensitivity to the drugs and during pregnancy and lactation  The COMT inhibitors are used with caution in patients with hypertension,hypotension, and decreased hepatic or renal function

 Gives advice and helps maintaining all aspects relating to activities of daily living.  both at work and at home, with the aim of maintaining work and family relationships, encouraging self-care where appropriate.

 To help improve gait, balance and flexibility  Improve aerobic activity and movement initiation  Increase independence and provide advice re fall prevention and other safety information.

 improving loudness and intelligibility of speech where possible.  Ensuring methods of communication are available as the disease progresses and to help with swallowing.

Observe the patient's mood, cognition; organization and general well being.  Observe for features of depression  Patients should not be forced into situations in which they feel ashamed of their appearance.  Encourage the patient to participate in moderate exercises.  Relaxation therapy

 Deep brain stimulation  Connected to pacemaker which delivers a constant current.  Is safe and efficacious.

 Mutations in the LRRK2, PARK2, PARK7, PINK1, and SNCA genes cause Parkinson disease.  Stem cell therapy hold the promise of treating disease by growing new tissues and organs from stem cells.

 Lisuride Patch to Treat Parkinson's Disease  This study has been completed In August 6, 2004 Last Updated: October 25, 2007  Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)  Information provided by: National Institutes of Health Clinical Center (NIHCC)

  ent ene Ther Aug;7(4): 